Now in its 15th year!
The 2013 meeting of the highly successful International Workshop on Co-morbidities & Adverse Drug Reactions in HIV.
Follow us on Twitter
International Medical Press is now on Twitter. Join our conversation today.
Data published quickly
AVT articles can now be published immediately online within 1 working day from acceptanceEditors-in-Chief: Douglas D Richman & Joep MA Lange
Antiviral Therapy (an official publication of the International Society of Antiviral Research) is an international, peer-reviewed journal devoted to publishing articles on the clinical development and use of antiviral agents and vaccines, and the treatment of all viral diseases. Antiviral Therapy is one of the leading journals in virology and infectious diseases (2011 ISI impact factor: 3.16).
The journal is comprehensive, and publishes articles concerning all clinical aspects of antiviral therapy. It features editorials, original research papers, specially commissioned review articles, letters and book reviews. The journal is aimed at physicians and specialists interested in clinical and basic research.
Features
♦ Immediate online publication
♦ A leading Editorial Board ensuring high-quality standards
♦ Worldwide readership
♦ Inclusion in major indexing and abstracting services
♦ No page charges
Recently published
Boosted protease inhibitors (PIs) offer a potential low-cost and practical alternative as second-line therapy in HIV. Two articles published in Antiviral Therapy explore lopinavir/ritonavir (LPV/r) monotherapy following initial treatment failure. Bunupuradah et al. found a lower proportion of patients achieved undetectable HIV RNA with LPV/r compared with those on a TDF-containing regimen. Similarly, Gilks et al. report higher rates of low-level viraemia with LPV/r versus combination therapy, despite comparable CD4+ T-cell response between groups. Non-inferiority of PI monotherapy could not be demonstrated against standard combination treatment. Until further research is conducted, the authors recommend against PI monotherapy as second-line.
The Editorial Office welcomes queries about publishing supplements within the journal. Please visit the Supplements page for more information.
ISSN: 1359-6535 (print); 2040-2058 (online)